Clinical trials: Placebo Response
Spasticity, Multiple Sclerosis
A Study of the Safety and Effectiveness of Sativex®, for the Relief of Symptoms of Spasticity in Subjects, From Phase B, With Multiple Sclerosis (MS)
The purpose of this study is to determine whether Sativex® versus Placebo is effective in the relief of symptoms of spasticity in subjects with multiple sclerosis, who have been identified as having a capacity to respond to…
- Trial name
- NCT00681538
- Testing
- Sativex®
- Where
- United Kingdom
- Volunteers
- 572 people
- Sponsor
- Jazz Pharmaceuticals
Vitreoretinal Traction Syndrome
Study to Evaluate Plasmin for the Creation of a Posterior Vitreous Detachment
Plasmin is expected to create a posterior vitreous detachment. The pharmacological creation of a posterior vitreous detachment may be beneficial in a variety of conditions.
- Trial name
- NCT00348439
- Testing
- Plasmin, Vehicle
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Bausch & Lomb Incorporated
Primary Immune Thrombocytopenia
A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed Steroids
The purpose of this study is to evaluate the effect of two different doses of ianalumab added to eltrombopag to prolong Time to Treatment Failure (TTF) in adults with primary ITP who failed previous first-line treatment with…
- Trial name
- VAYHIT2 (NCT05653219)
- Testing
- Ianalumab, Eltrombopag
- Where
- 74 sites in United States, Argentina and 22 more
- Volunteers
- 152 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
A Study To Assess The Effect Of PF-03526299 On Lung Function Following An Allergen Challenge In Asthmatic Subjects
PF-03526299, a novel anti-inflammatory agent should attenuate the effect of a bronchial allergen challenge on lung function and hence provide proof of mechanism for this agent.
- Trial name
- NCT00877539
- Testing
- PF-03526299, Fluticasone propionate
- Where
- 2 sites in United Kingdom
- Volunteers
- 29 people
- Sponsor
- Pfizer
Sepsis and Coagulopathy
The Safety And Efficacy of ART-123 in Subjects With Sepsis and Coagulopathy
The purpose of the study is to evaluate if ART-123 given to patients who have severe sepsis can decrease mortality.
- Trial name
- Scarlet2 (NCT03517501)
- Testing
- ART-123
- Sponsor
- Asahi Kasei Pharma America Corporation
Major Depressive Disorder, MDD
A Study to Assess the Long- Term Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder
The purpose of this study is to determine if TC-5214 or placebo (a tablet that looks like medicine tablet or capsule, but contains no active medicine) is safe and effective when taken for 52 weeks with another antidepressant…
- Conditions
- Major Depressive Disorder, MDD, Depression
- Trial name
- NCT01152554
- Testing
- TC-5214
- Where
- 94 sites in United States, Puerto Rico
- Volunteers
- 813 people
- Sponsor
- AstraZeneca
Healthy Volunteers
A Phase 1 TR-701 FA Study of Blood Pressure Response Post Tyramine Challenge
Phase 1 study to determine the effect of oral TR-701 FA on SBP response when administered with tyramine
- Trial name
- NCT01539473
- Testing
- TR-701 FA with Tyramine
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Migraine
Study of Telcagepant (MK-0974) in Participants With Moderate to Severe Acute Migraine With or Without Aura (MK-0974-011)
The purpose of this study is to investigate the efficacy and safety of telcagepant (MK-0974) compared to an approved medication for acute migraine.
- Trial name
- NCT00442936
- Testing
- Telcagepant potassium 150 mg, Telcagepant potassium 300 mg, Zolmitriptan 5 mg
- Volunteers
- 1,380 people
- Sponsor
- Merck Sharp & Dohme LLC
Rheumatoid Arthritis
Study of Two Doses of ABX464 in Participants With Moderate to Severe Rheumatoid Arthritis
This Phase IIa study aims at investigating the safety and tolerability of 2 dose-levels of ABX464 administered daily in combination with methotrexate (MTX) in patients with moderate to severe active Rheumatoid Arthritis (RA) who…
- Trial name
- NCT03813199
- Testing
- ABX464 50mg, ABX464 100mg, Methotrexate
- Where
- 24 sites in Belgium, Czechia and 3 more
- Volunteers
- 60 people
- Sponsor
- Abivax S.A.
Rheumatoid Arthritis
Safety and Efficacy of Pf-06650833 In Subjects With Rheumatoid Arthritis, With An Inadequate Response To Methotrexate
This is a Phase 2, multicenter, randomized, double blind, double dummy, placebo and active-controlled, parallel group study to assess the efficacy and safety of PF 06650833 at Week 12 in subjects with moderate-severe, active, RA…
- Trial name
- NCT02996500
- Testing
- PF-06650833, Tofacitinib
- Where
- 103 sites in United States, Australia and 17 more
- Volunteers
- 269 people
- Sponsor
- Pfizer
Papillomavirus Infections
Efficacy of 851B Gel for Treating High-Risk Cervical Human Papillomavirus Infection in Women.
The purpose of this study was to evaluate efficacy of 851B gel over a range of concentrations and dosing regimens on high-risk cervical human papillomavirus infection in women.
- Trial name
- NCT00117884
- Testing
- 851B
- Where
- 23 sites in United States, Canada
- Volunteers
- 240 people
- Sponsor
- Takeda
Rheumatoid Arthritis
A Study to Assess Immune Response Following Zoster Vaccination to Subjects With Rheumatoid Arthritis Receiving Tofacitinib or Placebo With Background Methotrexate
This study will evaluate immune response following administration of zoster vaccine in subjects with rheumatoid arthritis who are receiving background methotrexate and initiate 5 mg twice daily of tofacitinib or placebo for…
- Trial name
- NCT02147587
- Testing
- Tofacitinib
- Where
- 36 sites in United States
- Volunteers
- 112 people
- Sponsor
- Pfizer
Cervical Intraepithelial Neoplasia
A Study of RO5217790 in Participants With High Grade Cervical Intraepithelial Neoplasia (CIN) Associated With High Risk Human Papillomavirus (HR-HPV) Infection
This randomized, double-blind, placebo-controlled, parallel arm study will assess the safety and the efficacy of RO5217790 on histologic resolution in participants with high grade CIN associated with HR-HPV infection.
- Trial name
- NCT01022346
- Testing
- RO5217790
- Where
- 66 sites in United States, Belgium and 4 more
- Volunteers
- 206 people
- Sponsor
- Hoffmann-La Roche
Congestive Heart Failure, Anemia
Subcutaneous (SC) Darbepoetin Alfa in Subjects With Symptomatic Congestive Heart Failure (CHF) & Anemia
The purpose of this study is to evaluate whether weight-based or fixed starting doses result in comparable hemoglobin increases and treatment effects in patients with heart failure and anemia.
- Trial name
- NCT00086086
- Testing
- Darbepoetin Alfa
- Volunteers
- 150 people
- Sponsor
- Amgen
Pulmonary Disease, Chronic Obstructive
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Dose-Response Relationship of Multiple Doses of GSK2269557 Administered as a Dry Powder to Chronic Obstructive Pulmonary Disease (COPD) Patients
This is a randomised, double-blind, placebo controlled, parallel group study to evaluate the safety, tolerability, pharmacokinetics and dose response of multiple doses of GSK2269557 administered as a dry powder in COPD subjects.
- Trial name
- NCT02130635
- Testing
- GSK2269557 100 MCG, GSK2269557 500 MCG
- Where
- 2 sites in Germany
- Volunteers
- 64 people
- Sponsor
- GlaxoSmithKline
Semen Quality
A Clinical Trial Evaluating the Efficacy and Safety of Leflutrozole on Testicular Function
The goal of this clinical trial is to evaluate three doses of the drug leflutrozole on improvement of semen quality in men. It will also study the safety of leflutrozole.
- Trial name
- ETNA (NCT06993155)
- Testing
- Leflutrozole, Dose 1, Leflutrozole, Dose 2, Leflutrozole, Dose 3
- Where
- 4 sites in United States
- Volunteers
- 200 people
- Sponsor
- ReproNovo Aps
Migraine, Common Migraine
A Study of the Efficacy and Safety of Topiramate in the Prevention of Migraine
The purpose of this study is to evaluate the safety and efficacy of three doses of topiramate (50 milligrams[mg], 100mg, and 200mg per day) compared with placebo in the prevention of migraine.
- Conditions
- Migraine, Common Migraine, Classic Migraine, Headache
- Trial name
- NCT00231595
- Testing
- topiramate
- Volunteers
- 768 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Knee Osteoarthritis
Dose Escalation Study Assessing the Safety and Immune Response of PPV-06 Vaccine
PPV-06 immunotherapy targets interleukin-6 (IL-6), a key molecule of the immune system whose overproduction is implicated in many inflammatory and autoimmune diseases such as rheumatoid arthritis and osteoarthritis.
- Trial name
- NCT04447898
- Testing
- PPV-06 10 μg, PPV-06 50 μg
- Where
- France
- Volunteers
- 24 people
- Sponsor
- Peptinov SAS
Bipolar Depression
Lurasidone HCI - A 6-week Phase 3 Study of Patients With Bipolar I Depression
Lurasidone HCI is a compound that is a candidate for the treatment of bipolar I depression. This clinical study is designed to test the hypothesis that Lurasidone in combination with either Lithium or Divalproex is effective…
- Trial name
- PREVAIL3 (NCT01284517)
- Testing
- Lurasidone
- Where
- 75 sites in United States, Canada and 8 more
- Volunteers
- 356 people
- Sponsor
- Sumitomo Pharma America, Inc.
Alzheimer's Disease
Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild To Moderate Alzheimer's Disease
Rosiglitazone (RSG) has been tested and is approved as a treatment for type II diabetes mellitus, a disease that occurs when the body ineffectively uses glucose.
- Trial name
- NCT00428090
- Testing
- Rosiglitazone
- Where
- 138 sites in United States, Austria and 18 more
- Volunteers
- 862 people
- Sponsor
- GlaxoSmithKline